Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 26:14:17562864211037430.
doi: 10.1177/17562864211037430. eCollection 2021.

Efficacy and tolerability of antiseizure drugs

Affiliations
Review

Efficacy and tolerability of antiseizure drugs

Tahir Hakami. Ther Adv Neurol Disord. .

Abstract

Drug-resistant epilepsy occurs in 25-30% of patients. Furthermore, treatment with a first-generation antiseizure drug (ASD) fails in 30-40% of individuals because of their intolerable adverse effects. Over the past three decades, 20 newer- (second- and third-)generation ASDs with unique mechanisms of action and pharmacokinetic profiles have been introduced into clinical practice. This advent has expanded the therapeutic armamentarium of epilepsy and broadens the choices of ASDs to match the individual patient's characteristics. In recent years, research has been focused on defining the ASD of choice for different seizure types. In 2017, the International League Against Epilepsy published a new classification for seizure types and epilepsy syndrome. This classification has been of paramount importance to accurately classify the patient's seizure type(s) and prescribe the ASD that is appropriate. A year later, the American Academy of Neurology published a new guideline for ASD selection in adult and pediatric patients with new-onset and treatment-resistant epilepsy. The guideline primarily relied on studies that compare the first-generation and second-generation ASDs, with limited data for the efficacy of third-generation drugs. While researchers have been called for investigating those drugs in future research, epilepsy specialists may wish to share their personal experiences to support the treatment guidelines. Given the rapid advances in the development of ASDs in recent years and the continuous updates in definitions, classifications, and treatment guidelines for seizure types and epilepsy syndromes, this review aims to present a complete overview of the current state of the literature about the efficacy and tolerability of ASDs and provide guidance to clinicians about selecting appropriate ASDs for initial treatment of epilepsy according to different seizure types and epilepsy syndromes based on the current literature and recent US and UK practical guidelines.

Keywords: antiseizure drug; epilepsy; seizure types.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

Cited by

References

    1. Fisher RS, Acevedo C, Arzimanoglou A, et al.ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475–482. - PubMed
    1. Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia 2008; 49: 8–12. - PubMed
    1. Mattson RH, Cramer JA, Collins JF, et al.Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–151. - PubMed
    1. Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use. CNS Spectr 2004; 9: 110–119. - PubMed
    1. French JA, White HS, Klitgaard H, et al.Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia 2013; 54: 3–12. - PubMed

LinkOut - more resources